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On August 29th every year, just before the onset of the rains,
the devout Orthodox of Greece would celebrate the feast of
Ayios Ioannis o Rigologos - St John the Malariologist.
History does not record whether or not this devotion had
any greater effect than the remedy of the more pragmatic
Victorian Cambridgeshire Fenmen, who, on market day,
“would stand in a druggist’s shop … and lay down their
pence for a small packet of opium” [1]. The origin of
mal’aria, the ague of the Fenman, was obvious to all - bad
air, a “miasmatic emanation in the air” [2]. We may snigger
at these hypotheses today, but malaria was then, as today,
predominantly a disease of the poor. They did not command
the attention of scientists and doctors then, any more than
today they command the priorities of the major pharma-
ceutical companies, or, until the last decade or so, of many
scientists. The idea that an insect could transmit disease was
preposterous until Patrick Manson’s demonstration, in the
1870s, that mosquitoes were the vector of filarial worms, the
causative agent of elephantiasis. It was to fall to Ronald
Ross, working in India, and Giovani Grassi, in Italy, to show
- in the late 1890s - that anopheline mosquitoes transmitted
the malaria parasite (itself discovered only in 1880 by
Alphonse Laveran).
We might be congratulated on how far we have come in the
last century or so in our understanding of malaria. We might
- were it not for the fact that the burden of malaria remains
heavy, not in the Cambridgeshire Fens or the Pontine
Marshes, but in much of sub-Saharan Africa, in Asia and in
South America. The impact of malaria in Africa is horrific: it
kills over one million children under five every year. Wen
Kilama, now Chair of the African Malaria Vaccine Testing
Network, puts this in perspective: “It is like loading up seven
Boeing 747 airliners each day, then deliberately crashing
them into Mount Kilimanjaro” (quoted in [3]). The vast
majority of those who die are among the poorest of society
[4]. The impact of malaria, and other vector-borne diseases,
to families and economies is simply appalling and cannot be
ignored.
Ignored, of course, it has not been. Environmental engineers
have drained marshes, entomologists have sprayed insecti-
cides from the Cape to Cairo, immunologists have spent mil-
lions in the elusive search for a vaccine, pharmacologists
have developed (a few) new drugs to kill the parasite, hoping
against hope that they can outwit natural selection [5]. Hun-
dreds of dedicated malariologists have devoted their careers
to combating malaria. Yet, as Robert Desowitz so graphically
tells us, the situation is now getting worse, not better [6]. In
the 1960s, for example, malaria had been all but eradicated
in India and Sri Lanka; today there are some 20,000 deaths
a year due to malaria in India alone [7]. In the latter part of
this period the proportion of monies the United States
Agency for International Development (USAID) spent on
malaria fell from 11% in 1985 ($49 million in 1992 money) to
1.8% in 1994 ($9.7 million) [8]. Thankfully, the tide may
now be turning, with several high-profile initiatives to
control malaria [9,10].
In the heady days of molecular biology few were attracted to
study tropical diseases; neither species of Plasmodium nor
mosquitoes were models for anything but themselves. It is
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The genomes of the malaria parasite, its vector and its host are now sequenced. This has been a
tremendous scientific achievement. But will it offer hope to the millions who die from malaria each
year? Yes, but only if combined with political will and social change.only a dozen years ago that both individual scientists and
some funding agencies began to argue that the application of
molecular techniques to the study of both parasites and their
vectors might eventually have an impact on malaria. I rarely
praise administrators, but we must give great credit to those
in the MacArthur Foundation, World Health Organization
(WHO) and the Wellcome Trust who backed a small band of
scientists who were willing to pioneer the use of modern bio-
logical techniques to study malaria. Credit, because they
were very strongly criticized for doing so, for diverting
monies from more practical studies of malaria control, for
example of the efficacy of insecticide-impregnated bednets
(see, for example, [11]). The criticism was understandable:
few of the scientists involved had any first-hand experience
of malaria, all were using technologies beyond the wildest
dreams of scientists in the countries where malaria is
endemic and none could promise any practical benefit
within decades. Only a few seriously engaged with scientists
from the countries where malaria is endemic.
The publication of the “complete” genomic sequences of
Anopheles gambiae, the most important of the vectors of
malaria [12], and of two species of Plasmodium including
Plasmodium falciparum, the most dangerous of the para-
sites of man [13] and P. yoelii, one of the best model para-
sites [14], together with that of human, is the end of the
beginning of the efforts initiated in the early 1990s to study
the fundamental biology of these organisms. Their publica-
tion was accompanied by the self-congratulatory hyperbole
that is now customary on such occasions, spiced by rivalries
between journals and between funding agencies and by the
extraordinary profusion of honorary authors on these
papers. These honorary authors should be ashamed of them-
selves - they devalue the enormous efforts of those who did
the work.
But let us put all of that aside. Mosquitoes are extraordinar-
ily abundant and versatile organisms. Most, though not all,
are blood-feeders and thus wonderfully adapted to transmit
blood-borne parasites, be they viruses, protozoa or nema-
tode worms. Indeed the US even considered Aedes aegypti
as a vector of biological warfare agents [15]. (I am not giving
any credence to the malicious and politically motivated
claims that they did so in India, thereby derailing what
promised to be very informative trials of mosquito control by
the sterile insect technique [16-18].) One approach to
disease control is to eliminate - or emasculate - these
vectors. Indeed that was almost achieved in many places, by
insecticides, by the early 1960s. Then nature kicked back
with insecticide-resistant mosquitoes, and the institutions of
the WHO and other agencies were simply too hide-bound to
cope (see [19] for an insider’s account of the failure of the
WHO’s eradication campaign). Today she is kicking back
again - developing resistance to the pyrethroids used, to
such good effect, to impregnate bednets, extensively used for
control in Vietnam and in some parts of Africa. 
The parasites
Plasmodium is the first of the Protoctista to be sequenced,
the first of an extraordinarily diverse kingdom of some 30
phyla. Sequencing the genome of Plasmodium falciparum is
a major technical achievement - not least because its assem-
bly was so tough, because the genome is 80.6% A+T. The
hope is that this sequence will offer new targets for both
antimalarial drugs and vaccines. This hope is far from a day-
dream: antimalarials in clinical use target only three aspects
of the metabolism of Plasmodium, heme breakdown (tar-
geted, for example, by chloroquine and artemisinins), folate
biosynthesis (by sulphonamides) and electron transport (by
atovaquone, for example); Gardner and colleagues identify,
from their analysis of the metabolism of P. falciparum [13],
at least 10 other classes of target, including some in the api-
coplast, the extraordinary organelle derived from a plastid
used by the parasite for both fatty acid biosynthesis and for
the mevalonate-independent biosynthesis of isoprenoids
[20]. 
The search for a vaccine against malaria has been long and
arduous. Some thirty or so parasite proteins are now target
antigens for vaccines and the genome offers many more.
There are some 236 genes, in three families, encoding pro-
teins that are expressed on the surface of infected erythro-
cytes [13]. These genes are mostly sub-telomeric in location
and these regions, which may be up to 70 kilobases in
length, promiscuously recombine between chromosomes -
presumably in an adaptation to generate variation so as to
evade the host’s immune response to infection. Gardner et
al. [13] predict that the sequence offers “hundreds” of poten-
tial novel targets for vaccines; now the trick will be to mine
the proteome of Plasmodium for the identification of those
targets that are not hypervariable.
None of these efforts, to develop new antimalarials or effec-
tive vaccines, will impact malaria unless they are available in
the countries where the disease is endemic. There is no
doubt that they will impact tourist malaria, but that is rela-
tively trivial. The political challenge is not only to encourage
research but also to ensure that its products are not simply
used to bolster the share prices of multinational pharmaceu-
tical companies, as we have already seen with agents active
against human immunodeficiency virus (HIV). The Agree-
ment on Trade Related Aspects of Intellectual Property
(THRIPS) is a major barrier to the provision of affordable
drugs to the world’s poor; and the US government continues
to block the implementation of the Doha Declaration, which
states that public health has precedence over the patent
rules of the World Trade Organization [21].
The vectors 
As a Drosophila geneticist I rejoice in the genomic sequence
of another fly, albeit one with whom Drosophila has not
enjoyed a common ancestor for 250 million years or so.
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least the rather surprisingly low fraction of predicted pro-
teins in A. gambiae that have clear orthologs in Drosophila
melanogaster (47%), despite very considerable conservation
of synteny between the two species [22]. There has been con-
siderable interest in engineering mosquitoes to be, for
example, resistant to parasites, and then attempting to drive
the responsible transgene into natural populations (see [23-
25]). For this even to be a starter knowledge of the popula-
tion structure of the vectors is vital. Many mosquito ‘species’
have very complex populations, and A. gambiae is no excep-
tion. These populations are speciating in front of our eyes;
not only are there seven sibling species that differ in ecology
and vectorial capacity, but there are species in statu
nascendi, to use Dobzhansky’s felicitous phrase. In Mali, for
example, A. gambiae sensu strictu exists in three reproduc-
tively isolated chromosomal forms, with clear evidence of
differential adaptation [26-28] and two characterized molec-
ular types (based on rDNA), and these classifications overlap
[27]. The strain of A. gambiae sequenced was, fortuitously,
one in which the genomes of two of these forms had been
mixed by laboratory crossing. This proved to give the
sequence assemblers some headaches [12], but has provided
researchers with a wealth of single-nucleotide polymor-
phisms (SNPs) for population studies. There can be no ques-
tion that the availability of these markers will be a stimulus
to studies of the population genetics and evolutionary
processes in this species complex, studies that will be of far
more than academic interest should either the sterile insect
technique or the release of genetically transformed flies
become a feasible control measure.
The host, and his responsibilities 
Was it worth it? As a biologist interested in fundamental
issues, one must, enthusiastically, answer ‘Yes’; for a malari-
ologist working in the field in a chronically underfunded lab
in Ouagadougou, I suspect the answer will be ‘No’, as she
would rather have a dissecting microscope or a Shop-Vac (a
hand-held vacuum cleaner for collecting resting mosqui-
toes). I have a strong hunch that malaria will not be defeated
by science, or at least, not by science alone, although I accept
the arguments of Carlos Morel, Director of Tropical Diseases
Research for WHO, that basic research is for the long, not
the short, term [29]. 
Yet, whatever the advances of science, the defeat of malaria,
as with so many diseases that primarily affect the poor and
disenfranchised, will depend upon political will, and on eco-
nomic and social reforms. It is no coincidence that malaria,
and many other vector-borne diseases, have been all but
eliminated from Europe and North America yet remain
scourges in the Third World; no coincidence that on the
Texan side of the Rio Grande there were 64 cases of mos-
quito-transmitted dengue fever in two decades (1980-1999)
but over 60,000 cases in the Mexican states immediately to
the south of the Rio Grande [30]. It would cost about $470
million per year to provide free insecticide-treated bednets
to all in rural tropical Africa; this is about half of the amount
spent ($860 million) on the control of cat fleas in the USA
(C. Curtis, personal communication; the cat flea control
figure is based on data from MK Rust, University of Califor-
nia Riverside). Bednets will not eliminate malaria - but they
will have an immediate and dramatic effect on morbidity
and mortality. But I must not end on so pessimistic a note.
The greatest achievement of the last decade, an achievement
crowned by the publication and analyses of the genomes of
parasite, vector and host, has been to bring malaria to the
centre stage of modern biology: to paraphrase the words of
Sam Weller, we now “know wot’s wot, we does” [31]. And
that must be good; it must offer hope.
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